Home LiteratureArticle Details
PMID: 27239288 Published · epublish English Journal Article Review

Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances.

F1000Research ·Vol. 5 ·2016-00-00

Dhanasekaran R, Bandoh S, Roberts LR

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality and has an increasing incidence worldwide. HCC can be induced by multiple etiologies, is influenced by many risk factors, and has a complex pathogenesis. Furthermore, HCCs exhibit substantial heterogeneity, which compounds the difficulties in developing effective therapies against this highly lethal cancer. With advances in cancer biology and molecular and genetic profiling, a number of different mechanisms involved in the development and progression of HCC have been identified. Despite the advances in this area, the molecular pathogenesis of hepatocellular carcinoma is still not completely understood. This review aims to elaborate our current understanding of the most relevant genetic alterations and molecular pathways involved in the development and progression of HCC, and anticipate the potential impact of future advances on therapeutic drug development.

Keywords
HCC hepatocellular carcinoma liver cancer
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Dhanasekaran Renumathy
Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.
Bandoh Salome
Department of Medicine, Korle-Bu Teaching Hospital, Accra, Ghana.
Roberts Lewis R
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN, USA.
References (149)
149 references, click to expand
  1. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.
    Genes Dev. 2004 Nov 1;18(21):2627-38 PMID: 15520282
  2. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Int J Cancer. 2015 Mar 1;136(5):E359-86 PMID: 25220842
  3. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.
    Semin Cancer Biol. 2014 Jun;26:78-88 PMID: 24457013
  4. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein.
    Gastroenterology. 2007 Apr;132(4):1476-94 PMID: 17408664
  5. N(6)-methyladenosine Modulates Messenger RNA Translation Efficiency.
    Cell. 2015 Jun 4;161(6):1388-99 PMID: 26046440
  6. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.
    J Hepatol. 2010 Sep;53(3):568-77 PMID: 20646772
  7. Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma.
    J Gastroenterol. 2002;37(11):883-7 PMID: 12483242
  8. WNT/beta-catenin signaling in liver health and disease.
    Hepatology. 2007 May;45(5):1298-305 PMID: 17464972
  9. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma.
    Biomed Res Int. 2013;2013:136106 PMID: 23762823
  10. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features.
    Mod Pathol. 2013 Dec;26(12):1586-93 PMID: 23640129
  11. Genes associated with recurrence of hepatocellular carcinoma: integrated analysis by gene expression and methylation profiling.
    J Korean Med Sci. 2011 Nov;26(11):1428-38 PMID: 22065898
  12. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma.
    Int J Clin Pract. 2008 Aug;62(8):1212-8 PMID: 18479363
  13. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation.
    Med Oncol. 2012 Sep;29(3):1810-6 PMID: 21678027
  14. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.
    Science. 2014 Feb 28;343(6174):1010-4 PMID: 24578576
  15. Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis.
    World J Gastroenterol. 2014 Jun 28;20(24):7971-8 PMID: 24976734
  16. Differential DNA methylation associated with hepatitis B virus infection in hepatocellular carcinoma.
    Int J Cancer. 2007 Sep 15;121(6):1257-64 PMID: 17534893
  17. Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma.
    Hepatology. 2011 Oct;54(4):1227-36 PMID: 21688285
  18. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival.
    Clin Cancer Res. 2008 Jan 15;14(2):419-27 PMID: 18223217
  19. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.
    Hepatology. 2011 Aug;54(2):463-71 PMID: 21538440
  20. Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation.
    Cancer Lett. 2012 Aug 28;321(2):154-61 PMID: 22326283
  21. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
    PLoS One. 2012;7(5):e36713 PMID: 22615798
  22. Identification of driver genes in hepatocellular carcinoma by exome sequencing.
    Hepatology. 2013 Nov;58(5):1693-702 PMID: 23728943
  23. Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells.
    J Biol Chem. 2002 Jun 21;277(25):22573-80 PMID: 11960994
  24. Review of angiogenesis in hepatocellular carcinoma.
    Hepatol Res. 2015 Jan;45(1):1-9 PMID: 24533487
  25. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.
    Nat Genet. 2012 May 27;44(7):765-9 PMID: 22634754
  26. A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma.
    Cancer. 2012 Aug 15;118(16):3984-92 PMID: 22180222
  27. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
    J Clin Invest. 2006 Jun;116(6):1582-95 PMID: 16710476
  28. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway.
    Liver Int. 2012 May;32(5):752-60 PMID: 22276989
  29. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans.
    Hepatology. 2011 Nov;54(5):1679-89 PMID: 21769904
  30. Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin.
    Hepatology. 2013 May;57(5):1882-92 PMID: 23239537
  31. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma.
    Nat Genet. 2011 Aug 07;43(9):828-9 PMID: 21822264
  32. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma.
    Hepatol Res. 2003 Dec;27(4):309-314 PMID: 14662119
  33. Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma.
    Biochem Biophys Res Commun. 2005 Nov 11;337(1):337-42 PMID: 16199221
  34. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention?
    Epigenomics. 2011 Apr;3(2):235-43 PMID: 22122284
  35. Regulating the p53 system through ubiquitination.
    Oncogene. 2004 Mar 15;23(11):2096-106 PMID: 15021897
  36. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.
    Genome Res. 2013 Sep;23 (9):1422-33 PMID: 23788652
  37. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis.
    JAMA. 2008 Jan 2;299(1):53-60 PMID: 18167406
  38. Telomerase gene mutations are associated with cirrhosis formation.
    Hepatology. 2011 May;53(5):1608-17 PMID: 21520174
  39. The changing pattern of epidemiology in hepatocellular carcinoma.
    Dig Liver Dis. 2010 Jul;42 Suppl 3:S206-14 PMID: 20547305
  40. p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection.
    Intervirology. 2004;47(1):26-31 PMID: 15044833
  41. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
    Hepatology. 2002 Jul;36(1):150-5 PMID: 12085359
  42. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis.
    Arch Pathol Lab Med. 2000 Jul;124(7):1061-5 PMID: 10888784
  43. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.
    Gastroenterology. 2004 Oct;127(4):1110-22 PMID: 15480989
  44. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.
    Genome Res. 2012 Apr;22(4):593-601 PMID: 22267523
  45. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Mol Carcinog. 2002 Oct;35(2):85-92 PMID: 12325038
  46. Viral-human chimeric transcript predisposes risk to liver cancer development and progression.
    Cancer Cell. 2014 Mar 17;25(3):335-49 PMID: 24582836
  47. The role of signaling pathways in the development and treatment of hepatocellular carcinoma.
    Oncogene. 2010 Sep 9;29(36):4989-5005 PMID: 20639898
  48. Liver cancer in 2013: Mutational landscape of HCC--the end of the beginning.
    Nat Rev Clin Oncol. 2014 Feb;11(2):73-4 PMID: 24395088
  49. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes.
    Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4262-7 PMID: 14999097
  50. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Hepatology. 2010 Jun;51(6):1972-8 PMID: 20209604
  51. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
    Nat Genet. 2014 Dec;46(12):1267-73 PMID: 25362482
  52. Parkin gene alterations in hepatocellular carcinoma.
    Genes Chromosomes Cancer. 2004 Jun;40(2):85-96 PMID: 15101042
  53. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Cancer Discov. 2015 Apr;5(4):424-37 PMID: 25776529
  54. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
    Oncogene. 2007 Apr 2;26(15):2166-76 PMID: 17401425
  55. Tumor-infiltrating T lymphocytes: friends or foes?
    Lab Invest. 2006 Mar;86(3):231-45 PMID: 16446705
  56. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis.
    Clin Gastroenterol Hepatol. 2005 Nov;3(11):1150-9 PMID: 16271348
  57. Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas.
    J Virol. 1987 Dec;61(12):3848-54 PMID: 2824819
  58. The two faces of transforming growth factor beta in carcinogenesis.
    Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 PMID: 12861075
  59. The hepatitis B virus X protein functionally interacts with CREB-binding protein/p300 in the regulation of CREB-mediated transcription.
    J Biol Chem. 2007 Feb 16;282(7):4277-87 PMID: 17158882
  60. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
    Hepatology. 2010 Nov;52(5):1680-9 PMID: 20725905
  61. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients.
    Hepatology. 2014 Mar;59(3):911-23 PMID: 24114970
  62. Promoter methylation of the secreted frizzled-related protein 1 gene SFRP1 is frequent in hepatocellular carcinoma.
    Cancer. 2006 Aug 1;107(3):579-90 PMID: 16795071
  63. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression.
    J Int Med Res. 2011;39(6):2119-28 PMID: 22289527
  64. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma.
    Hepatology. 2008 Apr;47(4):1211-22 PMID: 18318435
  65. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
    Mod Pathol. 2015 Jun;28(6):822-9 PMID: 25698061
  66. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma.
    Nature. 1990 Feb 8;343(6258):555-7 PMID: 1967822
  67. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase.
    Proc Natl Acad Sci U S A. 2001 Jan 30;98 (3):974-9 PMID: 11158580
  68. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling.
    Genes Chromosomes Cancer. 2013 Mar;52(3):225-36 PMID: 23109092
  69. MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival.
    PLoS One. 2013 Jul 29;8(7):e68744 PMID: 23922662
  70. Constitutional telomerase mutations are genetic risk factors for cirrhosis.
    Hepatology. 2011 May;53(5):1600-7 PMID: 21520173
  71. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18.
    J Biol Chem. 2012 Jul 27;287(31):26302-11 PMID: 22685290
  72. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection.
    Int J Surg. 2014;12(7):659-65 PMID: 24866078
  73. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis.
    J Clin Invest. 2012 Aug;122(8):2884-97 PMID: 22820290
  74. miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes.
    Antiviral Res. 2010 Oct;88(1):119-23 PMID: 20637242
  75. Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis.
    Oncogene. 2004 Jan 8;23(1):142-8 PMID: 14712219
  76. Genomics and signaling pathways in hepatocellular carcinoma.
    Semin Liver Dis. 2007 Feb;27(1):55-76 PMID: 17295177
  77. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein.
    J Virol. 2002 Nov;76(22):11770-4 PMID: 12388740
  78. Epidemiology of hepatocellular carcinoma: consider the population.
    J Clin Gastroenterol. 2013 Jul;47 Suppl:S2-6 PMID: 23632345
  79. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
    Int J Cancer. 2011 Feb 15;128(4):887-96 PMID: 20473887
  80. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase.
    Nature. 2000 Dec 14;408(6814):869-73 PMID: 11130727
  81. Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma.
    Biomed Res Int. 2014;2014:780521 PMID: 24757675
  82. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.
    Cancer Res. 2009 Jul 15;69(14):5761-7 PMID: 19584283
  83. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.
    Hepatology. 2014 Jun;59(6):2188-95 PMID: 24375711
  84. Identification of potential driver genes in human liver carcinoma by genomewide screening.
    Cancer Res. 2009 May 1;69(9):4059-66 PMID: 19366792
  85. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
    Oncogene. 2011 Nov 24;30(47):4750-6 PMID: 21625215
  86. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection.
    J Transl Med. 2012 Jul 30;10:151 PMID: 22846613
  87. Hepatocellular carcinoma: molecular pathways and new therapeutic targets.
    Semin Liver Dis. 2005;25(2):212-25 PMID: 15918149
  88. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
    Cancer Res. 2009 Sep 15;69(18):7385-92 PMID: 19723656
  89. Obesity and diabetes as a risk factor for hepatocellular carcinoma.
    Liver Transpl. 2004 Feb;10(2 Suppl 1):S69-73 PMID: 14762843
  90. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma.
    Hepatology. 2009 May;49(5):1571-82 PMID: 19296470
  91. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
    Nat Genet. 2012 May 06;44(6):694-8 PMID: 22561517
  92. Cancer stem cells in the development of liver cancer.
    J Clin Invest. 2013 May;123(5):1911-8 PMID: 23635789
  93. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs.
    J Hepatol. 2013 Nov;59(5):1107-17 PMID: 23835194
  94. DNA methylation in hepatocellular carcinoma.
    World J Gastroenterol. 2008 Mar 21;14(11):1741-8 PMID: 18350605
  95. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers.
    Oncogene. 2003 Jun 12;22(24):3813-20 PMID: 12802289
  96. Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer.
    Hepatology. 2008 Jun;47(6):2059-67 PMID: 18506891
  97. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.
    Ann Surg Oncol. 2011 May;18(5):1243-50 PMID: 21327457
  98. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia.
    Hepatology. 2009 Feb;49(2):658-64 PMID: 19177576
  99. Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.
    Am J Epidemiol. 2013 Feb 15;177(4):333-42 PMID: 23355498
  100. Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma.
    Hum Mutat. 2008 May;29(5):703-8 PMID: 18320596
  101. Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas.
    Clin Cancer Res. 2002 Apr;8(4):1087-92 PMID: 11948118
  102. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
    Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6 PMID: 23530248
  103. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
    Clin Cancer Res. 2012 Sep 15;18(18):4997-5007 PMID: 22811581
  104. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.
    Hepatology. 2015 Oct;62(4):1160-73 PMID: 26154152
  105. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
    Hum Pathol. 2012 Sep;43(9):1425-35 PMID: 22406368
  106. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.
    Cell. 2009 Jun 12;137(6):1005-17 PMID: 19524505
  107. Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis.
    Oncotarget. 2014 Oct 15;5(19):9425-43 PMID: 25294808
  108. Role of histone H3 lysine 27 methylation in Polycomb-group silencing.
    Science. 2002 Nov 1;298(5595):1039-43 PMID: 12351676
  109. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma.
    Cancer Res. 1998 Jan 15;58(2):348-51 PMID: 9443416
  110. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice.
    Gut. 2005 Dec;54(12):1768-75 PMID: 16033879
  111. Mechanisms of polycomb gene silencing: knowns and unknowns.
    Nat Rev Mol Cell Biol. 2009 Oct;10(10):697-708 PMID: 19738629
  112. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.
    Eur J Cancer. 2004 Oct;40(15):2217-29 PMID: 15454246
  113. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.
    Hepatology. 2015 Jun;61(6):1945-56 PMID: 25645722
  114. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy.
    Hepatology. 2012 Dec;56(6):2231-41 PMID: 22706893
  115. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cancer Res. 2011 Jun 1;71(11):4028-39 PMID: 21512140
  116. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relationship to aflatoxin B1-DNA adducts and p53 mutation in hepatocellular carcinoma.
    Int J Cancer. 2003 Feb 10;103(4):440-4 PMID: 12478658
  117. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients.
    Cancer Res. 1999 Jan 1;59(1):71-3 PMID: 9892188
  118. MicroRNAs in hepatocellular carcinoma: regulation, function, and clinical implications.
    ScientificWorldJournal. 2013;2013:924206 PMID: 23431261
  119. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
    Gastroenterology. 2006 Apr;130(4):1117-28 PMID: 16618406
  120. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
    Nat Commun. 2013;4:2218 PMID: 23887712
  121. Hypoxia up-regulates SERPINB3 through HIF-2α in human liver cancer cells.
    Oncotarget. 2015 Feb 10;6(4):2206-21 PMID: 25544768
  122. Diabetes mellitus, obesity, and hepatocellular carcinoma: the jury is still out.
    Am J Gastroenterol. 2010 Sep;105(9):2116-7 PMID: 20818365
  123. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
    Oncogene. 2003 Jun 19;22(25):3911-6 PMID: 12813464
  124. Immunotherapeutic approaches to hepatocellular carcinoma treatment.
    Liver Cancer. 2012 Nov;1(3-4):226-37 PMID: 24159587
  125. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
    Nat Genet. 2015 May;47(5):505-11 PMID: 25822088
  126. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma.
    Cancer Sci. 2010 Jun;101(6):1501-10 PMID: 20345479
  127. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
    Sci Transl Med. 2013 Aug 7;5(197):197ra101 PMID: 23926199
  128. Role of hepatitis B virus DNA integration in human hepatocarcinogenesis.
    World J Gastroenterol. 2014 May 28;20(20):6236-43 PMID: 24876744
  129. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas.
    Cancer Lett. 2013 Nov 1;340(2):247-53 PMID: 23063663
  130. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
    Hepatology. 2012 Aug;56(2):622-31 PMID: 22370893
  131. The mTOR pathway in hepatic malignancies.
    Hepatology. 2013 Aug;58(2):810-8 PMID: 23408390
  132. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.
    Oncogene. 2008 Jan 3;27(1):85-97 PMID: 17599042
  133. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Cancer Res. 2006 Dec 15;66(24):11851-8 PMID: 17178882
  134. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma.
    Oncogene. 2005 Sep 22;24(42):6406-17 PMID: 16007195
  135. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells.
    J Hepatol. 2008 May;48(5):780-91 PMID: 18313787
  136. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
    Nat Genet. 2012 May 27;44(7):760-4 PMID: 22634756
  137. The role of hypoxia inducible factor-1 in hepatocellular carcinoma.
    Biomed Res Int. 2014;2014:409272 PMID: 25101278
  138. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation.
    Cell Stem Cell. 2011 Jul 8;9(1):50-63 PMID: 21726833
  139. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma.
    Br J Cancer. 2005 May 9;92 (9):1754-8 PMID: 15856046
  140. Activation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma.
    Hepatology. 2015 Apr;61(4):1269-83 PMID: 25503294
  141. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.
    Mol Med. 2011 Jan-Feb;17 (1-2):12-20 PMID: 20844838
  142. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
    Hepatology. 2013 Aug;58(2):706-17 PMID: 23505090
  143. Telomerase and human tumorigenesis.
    Semin Cancer Biol. 2000 Dec;10(6):399-406 PMID: 11170862
  144. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma.
    Cancer Res. 2014 Apr 1;74(7):1890-4 PMID: 24638984
  145. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.
    Cancer Cell. 2006 Aug;10(2):99-111 PMID: 16904609
  146. p53 mutation in hepatocellular carcinoma after aflatoxin exposure.
    Lancet. 1991 Nov 30;338(8779):1356-9 PMID: 1682737
  147. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
    Cancer Res. 2009 Oct 15;69(20):8067-75 PMID: 19826049
  148. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma.
    Gastroenterology. 2005 Nov;129(5):1375-83 PMID: 16285938
  149. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
    Clin Cancer Res. 2012 Apr 15;18(8):2290-300 PMID: 22374331
Article Info
Journal
F1000Research
Abbr.
F1000Res
ISSN
2046-1402
DOI
10.12688/f1000research.6946.1
Published
2016-00-00
Epub
2016-00-12
Language
English
Region
England
NLM ID
101594320
PMCID
PMC4870992
External Links
PubMed source DOI: 10.12688/f1000research.6946.1 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2